Aethlon Medical Stock Earnings Reports

Aethlon Medical reported progress in its fiscal Q1 2026 update centered on advancing its Hemopurifier program. Key clinical progress: the Australian oncology trial (patients with solid tumors not responding to anti-PD-1 therapy) completed the first cohort (3 patients) with no device-related serious adverse events or dose-limiting toxicities; an independent DSMB recommended progression to cohort 2 (two treatments in one week). Sites are actively screening under an amended protocol that expands eligibility to patients on monotherapy or combination anti-PD-1 regimens. Central lab analyses (extracellular vesicle levels and T cell function) from the first cohort are expected to yield early observations around September 2025. Preclinical results: ex vivo work showed 98.5% removal of platelet-derived extracellular vesicles in a simulated 4-hour Hemopurifier session, and poster data indicate GNA-binding EVs from long COVID patients—supporting expanded R&D interest in long COVID and other EV-mediated diseases. Strategic decision: Aethlon will not proceed with a planned parallel trial in India (despite CDSCO approval) due to expected delays and to avoid a potential regulatory impediment to a PMA/efficacy pathway; management expects this conserves roughly $0.5M–$1M and keeps focus on the faster Australian path. Financials: cash balance approximately $3.8M as of June 30, 2025; operating expenses fell ~32% year-over-year to $1.8M for the quarter driven by payroll and other cost reductions; clinical spending rose modestly. Outlook and funding: management expects to need additional capital in the future (ideally via strategic partnerships rather than pure finance raises) and targets completing Australian treatments late 2025/early 2026 to enable data analysis and next-step regulatory/partnering discussions.